AbbVie (ABBV) to invest USD 380mln in north Chicago to further expand active pharmaceutical ingredient manufacturing in the US; construction to begin in spring 2026, operational by 2029

AbbVie's announcement of a significant investment in active pharmaceutical ingredient manufacturing signals a strategic commitment to strengthening its domestic production capabilities.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Nvidia (NVDA) says collaborating with Akamai (AKAM), Forescout, Palo Alto Networks (PANW), Xage Security, and Siemens (SIE GY) to bring accelerated computing and AI

Hunterbrook Capital is long Generac (GNRC)

AbbVie (ABBV) to invest USD 380mln in north Chicago to further expand active pharmaceutical ingredient manufacturing in the US; construction to begin in spring 2026, operational by 2029

Newsquawk Daily Economic Releases - 24th February 2026

Mexican Economy Minister says they are better off tariff wise after last Friday as they went from paying 25% to 15% in non-USMCA goods

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move not only reflects the company's long-term growth strategy but also aligns with broader trends in reshoring production, which may enhance its supply chain resilience and potentially improve profit margins in the future.

Related headlines

The whole workspace, free to try.

Try it free